Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma

Researchers have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments. The five-drug combination targets multiple molecular pathways that diffuse large B-cell lymphoma (DLBCL) tumors use to survive.

source https://www.sciencedaily.com/releases/2024/06/240619182323.htm